Lilly, Astellas, Novo Nordisk and BMS strike further AI drug discovery deals
Lilly signed a $1.1 billion deal with Hong Kong's METiS TechBio for AI-based nanoparticle development, and Genome & Company also joined Lilly's AI platform. Astellas signed a $400 million deal with AI Proteins, Novo Nordisk is expanding its AI ties, and Pathos AI is working with Bristol Myers Squibb and Tempus AI.
Who is affected and how
- pharmaceuticals
- Large pharma companies treat milestone-based deals with external AI platforms as part of their R&D strategy.
- health policy
- A growing number of AI-driven drug candidates sharpens questions about approval and evidence.
Sources
- Genome & Company Joins Eli Lilly's AI Drug Discovery Platformseoul economic daily · Oct 20, 2026
- Genome & Company Joins Eli Lilly's AI Drug Discovery Platform - Seoul Economic Dailyen.sedaily.com · Oct 20, 2026
- UT System partners with clinical AI company – The Daily Texanthedailytexan.com · Oct 21, 2026
- LG Chem Shifts AI Drug Development Strategy to Clinical Patient Selection | Biobook Mediabiobookmedia.com · Oct 21, 2026
- Lilly partners with Hong Kong's Metis in $1.1B deal to bolster AI nanoparticle discovery - Fierce Biotechfiercebiotech.com · Oct 19, 2026 · magyar
- Lilly puts $1.1B on the line for Hong Kong biotech’s AI drug delivery platform - BioSpacebiospace.com · Oct 20, 2026 · magyar
- Astellas links up with AI Proteins in $400M computational drug discovery dealfierce biotech · Oct 21, 2026
- Novo Nordisk (CPSE:NOVO B) Deepens AI Drug Discovery Tiesyahoo finance · Oct 22, 2026
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.